Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Strategy and TPP

SCIO

Welcome to BBCR’s New Website!

December 7th, 2018 | Strategy and TPP
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Is Your Drug Development Strategy Built for Tomorrow’s Success?
  • BBCR assists companies with the identification and adoption of biomarkers, now a routine part of drug development, and especially valuable in rare disease and precision medicine product development. Reach out to us to learn how we can assist with your development project.
  • Partnering with BBCR Consulting means gaining the support of a specialized team committed to making the clinical trial process more efficient.
  • Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.
  • Accelerate Drug Development with Biomarker Strategy in Orphan Diseases and Precision Medicine

RSS Nasdaq Globe Newswire

  • OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 October 15, 2025
  • OSE Immunotherapeutics Reports First Half 2025 Financial Results October 15, 2025
  • Sitryx to participate in upcoming investor conferences October 15, 2025
  • Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septembre 2025 October 14, 2025
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2025 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs